Chemical subgroup
L01EA – BCR-ABL-Tyrosinkinase-Inhibitoren
7Decisions
10Patient groups
Added benefit by patient group
- Considerable1
- Minor2
- Non-quantifiable2
- Not proven5
Decisions, newest first
- 2026-05-21ScemblixAsciminibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-11-20ScemblixAsciminibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-03-16ScemblixAsciminibMinor
- 2021-11-19BosulifBosutinibNot proven
- 2020-11-20IclusigPonatinibNon-quantifiable
- 2020-11-20IclusigPonatinibNon-quantifiable
- 2019-02-21BosulifBosutinibNot proven: 2 of 2 patient groups
Data status: 2026-10-29